In a phase 1 study, the feasibility and efficacy of combining BRAF and MEK inhibitors (dabrafenib and trametinib) with the anti–PD-1 antibody pembrolizumab were evaluated in 15 patients with advanced BRAFV600-mutant melanoma who received the triple combination therapy (27). Here, MAP2K7 is linked to melanoma.